Altimmune (ALT) to Release Earnings on Thursday

Altimmune (NASDAQ:ALT) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Altimmune to post earnings of ($0.34) per share for the quarter.

Altimmune Price Performance

Shares of ALT opened at $6.43 on Friday. The business’s fifty day moving average price is $7.06 and its 200 day moving average price is $7.18. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84. The stock has a market capitalization of $457.30 million, a PE ratio of -4.15 and a beta of 0.19.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Wednesday, February 5th. Finally, Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price on the stock. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $20.83.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.